Tanaka Masashi, Mokhtari Golnaz K, Terry Raya D, Balsam Leora B, Lee Keun-Ho, Kofidis Theo, Tsao Philip S, Robbins Robert C
Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, Calif, USA.
Circulation. 2004 Sep 14;110(11 Suppl 1):II200-6. doi: 10.1161/01.CIR.0000138390.81640.54.
Ischemia-reperfusion injury is an important risk factor for graft coronary artery disease (GCAD). We hypothesized that overexpression of SOD1 in donor hearts would suppress ischemia-reperfusion injury and thereby reduce GCAD.
In one series, donor hearts of C57BL/6 (H-2b) transgenic mice overexpressing human SOD1 or C57BL/6 wild-type mice were heterotopically transplanted into C57BL/6 recipients and procured after 4 hours of reperfusion (n=6 each). Superoxide, TNF-alpha, and MCP-1/CCL2 production were significantly reduced in the SOD1 transgenic donor heart recipients, and graft injury determined by serum CPK-MB levels was significantly decreased. Cardiomyocyte apoptosis and caspase-3 and caspase-9 activities were significantly decreased in these recipients; caspase-8 activity was unchanged. Fas ligand but not Fas expression was also reduced. In a second series, transgenic and wild-type hearts were transplanted into C-H-2bm12KhEg (H-2bm12) recipients, and then procured on day 56 (n=7 each). Cardiac graft beating was significantly better in the SOD1 transgenic donor heart recipients on days 28, 42, and 56 (but not day 14). Significant reduction in luminal narrowing, the intima/media ratio, and the percentage of diseased vessels was seen in the SOD1 transgenic donor heart recipients, and MCP-1/CCL2, ICAM-1, and VCAM-1 production were significantly reduced.
Overexpression of SOD1 attenuates both apoptosis and the inflammatory response during ischemia-reperfusion injury and therefore mitigates against the subsequent development of GCAD.
缺血再灌注损伤是移植冠状动脉疾病(GCAD)的重要危险因素。我们假设供体心脏中SOD1的过表达会抑制缺血再灌注损伤,从而减少GCAD。
在一组实验中,将过表达人SOD1的C57BL/6(H-2b)转基因小鼠或C57BL/6野生型小鼠的供体心脏异位移植到C57BL/6受体体内,并在再灌注4小时后获取心脏(每组n = 6)。SOD1转基因供体心脏受体中的超氧化物、肿瘤坏死因子-α和MCP-1/CCL2生成显著减少,由血清CPK-MB水平确定的移植损伤显著降低。这些受体中的心肌细胞凋亡以及caspase-3和caspase-9活性显著降低;caspase-8活性未改变。Fas配体表达降低,但Fas表达未改变。在第二组实验中,将转基因和野生型心脏移植到C-H-2bm12KhEg(H-2bm12)受体体内,然后在第56天获取心脏(每组n = 7)。在第28、42和56天(但第14天未出现),SOD1转基因供体心脏受体的心脏移植跳动明显更好。SOD1转基因供体心脏受体的管腔狭窄、内膜/中膜比值和病变血管百分比显著降低,MCP-1/CCL2、ICAM-1和VCAM-1生成显著减少。
SOD1的过表达减轻了缺血再灌注损伤期间的细胞凋亡和炎症反应,因此减轻了GCAD的后续发展。